(R)-tert-Butyl 4-hydroxyazepane-1-carboxylate | 1174020-39-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氮杂环庚烷
• 英文名称: (R)-tert-Butyl 4-hydroxyazepane-1-carboxylate
• 英文别名: tert-butyl (4R)-4-hydroxyazepane-1-carboxylate
• CAS: 1174020-39-3
• 化学式: C₁₁H₂₁NO₃
• mdl: MFCD07368610
• 分子量: 215.29
• InChiKey: CRFSWDBNKHNGGA-SECBINFHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.91
• 拓扑面积：
  49.8
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• BETA-LACTAMASE INHIBITORS
  申请人：Blizzard Timothy A.

  公开号：US20110294777A1

  公开（公告）日：2011-12-01

  Substituted bicyclic beta-lactams of Formula I: (I), are β-lactamase inhibitors, wherein a, X, R 1 and R 2 are defined herein. The compounds and pharmaceutically acceptable salts thereof are useful in the treatment of bacterial infections in combination with β-lactam antibiotics. In particular, the compounds can be employed with a β-lactam antibiotics (e.g., imipenem, piperacillin, or ceftazidime) against microorganisms resistant to β-lactam antibiotics due to the presence of the β-lactamases.

  化合物I的替代双环β-内酰胺(I)是β-内酰胺酶抑制剂，其中a、X、R1和R2如此定义。该化合物及其药学上可接受的盐在与β-内酰胺类抗生素联合治疗细菌感染方面是有用的。特别地，该化合物可与β-内酰胺类抗生素（例如亚胺培南、哌拉西林或头孢他啶）一起用于对抗由β-内酰胺酶存在而对β-内酰胺类抗生素产生耐药性的微生物。
• [EN] PYRAZOLO[1,5-A]PYRAZINE DERIVATIVES AS BTK INHIBITORS<br/>[FR] DÉRIVÉS DE PYRAZOLO[1,5-A]PYRAZINE UTILISÉS EN TANT QU'INHIBITEURS DE BTK
  申请人：BIOGEN MA INC

  公开号：WO2022104079A1

  公开（公告）日：2022-05-19

  Provided are compounds of Formula (I'): or pharmaceutically acceptable salts thereof, wherein the variables in the formula are as defined herein; and methods for their use and production.

  提供了公式（I'）的化合物或其药学上可接受的盐，其中公式中的变量如此处定义；以及它们的使用和生产方法。
• US8487093B2
  申请人：——

  公开号：US8487093B2

  公开（公告）日：2013-07-16
• [EN] THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS<br/>[FR] DÉRIVÉS DE THIÉNOPYRIDINE POUR LE TRAITEMENT ET LA PRÉVENTION D'INFECTIONS PAR LE VIRUS DE LA DENGUE
  申请人：SIGA TECHNOLOGIES INC

  公开号：WO2014089378A1

  公开（公告）日：2014-06-12

  Methods and pharmaceutical compositions for treating viral infections, by administering certain thienopyridine derivative compounds in therapeutically effective amounts are disclosed. Methods of using the compounds and pharmaceutical compositions thereof are also disclosed. In particular, the treatment of viral infections such as caused by flavivirus is disclosed, i.e., including but not limited to, Dengue virus, West Nile virus, yellow fever virus, Japanese encephalitis virus, and tick-borne encephalitis virus.